Rapport Therapeutics, Inc. Common Stock (RAPP) quarterly cash flow statement — complete operating, investing & financing history
Rapport Therapeutics, Inc. Common Stock (RAPP) cash flow statement — 4-year operating, investing & financing cash flows
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|
| Cash from Operations | -41.45M | -13.06M | -24.7M | -17.46M | -25.07M | -20.24M | -14.45M | -16.41M | -16.35M | -17.61M | -10.36M |
| Operating CF Margin % | - | -65.31% | - | - | - | - | - | - | - | - | - |
| Operating CF Growth % | -65.36% | 35.46% | -70.99% | -6.4% | -53.31% | -14.89% | -39.48% | - | - | - | - |
| Net Income | -56.62M | -19.86M | -33.76M | -26.93M | -26.73M | -24.06M | -19.98M | -17.54M | -18.12M | -22.67M | -13.52M |
| Depreciation & Amortization | 212K | 227K | 265K | 256K | 252K | 244K | 260K | 219K | 208K | 152K | 53K |
| Stock-Based Compensation | 7.2M | 6.96M | 5.69M | 4.74M | 4.39M | 4.04M | 3.21M | 3.18M | 2.35M | 1.49M | 998K |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -728K | 371K | -501K | 771K | 391K | -25K | 725K | -5.56M | -670K | 6.57M | 167K |
| Working Capital Changes | 8.47M | -765K | 3.61M | 3.7M | -3.37M | -433K | 1.34M | 3.28M | -123K | -3.16M | 1.94M |
| Change in Receivables | -235K | -58K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -3.68M | 2.31M | 1.18M | -179K | 1.03M | 185K | 648K | 46K | 94K | -1.13M | 725K |
| Cash from Investing | 25.6M | 37.94M | -174.32M | -56.78M | 22.6M | 21.03M | 31.93M | -53.04M | -107.1M | -41.93M | -78.66M |
| Capital Expenditures | -78K | -86K | -169K | -134K | -22K | -291K | -226K | -140K | -967K | -1.07M | -1.44M |
| CapEx % of Revenue | - | 0.43% | - | - | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 193K | 0 | 0 | 0 | 92K | 436K | 0 | 3.77M | 0 | 0 | 0 |
| Cash from Financing | 1.41M | 531K | 311K | 270.53M | -63K | 5K | 7K | -1.39M | 159.35M | 63.66M | -140K |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 1.59M | 804K | 311K | 270.47M | -63K | 5K | 7K | -1.39M | 159.07M | 63.94M | -6K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | -5K | 0 | 0 | 0 | -1K | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -181K | -273K | 0 | 63K | 0 | 0 | 0 | 0 | 283K | -283K | -134K |
| Net Change in Cash | -14.44M | 25.41M | -198.71M | 196.29M | -2.54M | 799K | 17.49M | -70.85M | 35.9M | 4.12M | -89.16M |
| Free Cash Flow | -41.53M | -13.15M | -24.87M | -17.6M | -25.09M | -20.53M | -14.67M | -16.55M | -17.32M | -18.69M | -11.79M |
| FCF Margin % | - | -65.73% | - | - | - | - | - | - | - | - | - |
| FCF Growth % | -65.52% | 35.96% | -69.51% | -6.31% | -44.88% | -9.85% | -24.4% | - | - | - | - |
| FCF per Share | -0.87 | -0.28 | -0.53 | -0.46 | -0.71 | -1.06 | -0.76 | -0.86 | -0.86 | -0.96 | -0.65 |
| FCF Conversion (FCF/Net Income) | 0.73x | 0.66x | 0.73x | 0.65x | 0.94x | 0.84x | 0.72x | 0.94x | 0.90x | 0.78x | 0.77x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |